

On September 2, 2026, the U.S. District Court for the Eastern District of New York issued a decision concerning Kaneka's U.S. Patent No. 7,829,080 (the "'080 Patent" or "Patent"). The court held that claims 5 and 15 of the '080 Patent are invalid for lack of enablement. Kaneka strongly disagrees with the decision and will vigorously pursue an appeal before the U.S. Court of Appeals for the Federal Circuit.

The '080 Patent protects certain compositions of reduced coenzyme Q10. Kaneka filed a patent infringement lawsuit against Cocystal Technology (Jiaxing) Co., Ltd. and Cocystal Health Industry (Zhejiang) Co., Ltd. (collectively, "CoCrystal"), alleging that CoCrystal's reduced coenzyme Q10 product, CoCrystal QH, infringed claims 5 and 15 of the '080 Patent. CoCrystal admitted infringement of those claims but challenged the validity of the Patent.

In its decision, the New York District Court focused on whether the Patent demonstrated utility across the full scope of the claims, including compositions containing reduced coenzyme Q11. Kaneka respectfully but strongly disagrees with the court's legal analysis and its interpretation of the scientific evidence and testimony supporting the utility and enablement of the claimed compositions.

Importantly, in separate litigation involving the same claims 5 and 15 of the same '080 Patent, the U.S. District Court for the District of Delaware expressly held that the '080 Patent is valid and found that competing reduced coenzyme Q10 products infringed those claims. Thus, two U.S. district courts have reached different conclusions regarding the validity of the same Patent. Kaneka will seek appellate review of the New York decision before the U.S. Court of Appeals for the Federal Circuit. Kaneka believes that the decision made by the U.S. District Court for the District of Delaware is appropriate and correct.

Kaneka intends to pursue the appeal vigorously and to present its legal and scientific position fully. The New York ruling should not be interpreted as permission for third parties to disregard Kaneka's intellectual property rights. Kaneka reserves all rights and will continue to monitor the market and take appropriate legal action against parties that infringe those rights.

There is no change to Kaneka's ability to manufacture, supply, or support Kaneka Ubiquinol®. Brand holders and customers may continue to rely on Kaneka for consistent quality, dependable supply, scientific expertise, and responsible stewardship of the Kaneka Ubiquinol® brand. Kaneka remains firmly committed to protecting its technology, customers, and business partners and will provide appropriate updates as the appeal proceeds.